O	0	7	Quality
O	8	10	of
O	11	15	life
O	16	21	among
O	22	27	women
O	28	37	diagnosed
O	38	42	with
O	43	49	breast
O	50	56	Cancer
O	56	57	:
O	58	59	A
O	60	70	randomized
O	71	79	waitlist
O	80	90	controlled
O	91	96	trial
O	97	99	of
O	100	112	commercially
O	113	122	available
B-intervention	123	129	mobile
I-intervention	130	133	app
I-intervention	133	134	-
I-intervention	134	143	delivered
I-intervention	144	155	mindfulness
I-intervention	156	164	training
O	164	165	.

O	166	169	The
O	170	177	primary
O	178	187	objective
O	188	191	was
O	192	194	to
O	195	203	evaluate
O	204	207	the
B-outcome-Measure	208	216	efficacy
O	217	219	of
O	220	232	commercially
O	233	242	available
O	243	249	mobile
O	250	253	app
O	253	254	-
O	254	263	delivered
O	264	275	mindfulness
O	276	284	training
O	285	286	(
O	286	289	AMT
O	289	290	)
O	290	291	,
O	292	300	compared
O	301	305	with
B-control	306	314	waitlist
I-control	315	322	control
I-control	323	324	(
I-control	324	326	WC
I-control	326	327	)
O	327	328	,
O	329	331	on
O	332	339	quality
O	340	342	of
O	343	347	life
O	348	349	(
O	349	352	QOL
O	352	353	)
O	354	359	among
O	360	365	women
O	366	375	diagnosed
O	376	380	with
O	381	387	breast
O	388	394	cancer
O	394	395	.

O	396	399	The
O	400	409	secondary
O	410	417	outcome
O	418	421	was
B-outcome-Measure	422	435	dispositional
I-outcome-Measure	436	447	mindfulness
O	447	448	.

O	449	459	Enrollment
O	459	460	,
O	461	464	app
O	465	476	utilization
O	476	477	,
O	478	481	and
O	482	487	study
O	488	498	completion
O	499	502	are
O	503	511	reported
O	512	514	as
O	515	526	feasibility
O	527	537	objectives
O	537	538	.

B-eligibility	539	544	Women
I-eligibility	545	554	diagnosed
I-eligibility	555	559	with
I-eligibility	560	566	breast
I-eligibility	567	573	cancer
I-eligibility	574	575	≤
I-eligibility	575	576	5
I-eligibility	577	582	years
O	583	584	(
O	584	585	n
O	586	587	=
B-total-participants	588	591	112
O	591	592	)
O	593	597	were
O	598	608	randomized
O	609	611	to
O	612	615	AMT
O	616	617	(
O	617	618	n
O	619	620	=
B-intervention-participants	621	623	57
O	623	624	)
O	625	627	or
O	628	630	WC
O	631	632	(
O	632	633	n
O	634	635	=
B-control-participants	636	638	55
O	638	639	)
O	639	640	,
O	641	645	over
O	646	647	8
O	648	653	weeks
O	653	654	,
O	655	659	with
O	660	661	4
O	662	667	weeks
O	668	670	of
O	671	677	follow
O	677	678	-
O	678	680	up
O	680	681	.

O	682	684	We
O	685	694	conducted
O	695	701	linear
O	702	707	mixed
O	708	715	effects
O	716	722	models
O	723	725	to
O	726	733	examine
O	734	739	group
O	740	742	by
O	743	754	observation
O	755	767	interactions
O	768	770	on
O	771	774	QOL
O	775	778	and
O	779	792	dispositional
O	793	804	mindfulness
O	805	807	at
O	808	816	baseline
O	816	817	,
O	818	824	during
O	825	837	intervention
O	838	839	(
O	839	840	5
O	840	841	-
O	841	846	weeks
O	846	847	)
O	847	848	,
O	849	853	post
O	853	854	-
O	854	866	intervention
O	867	868	(
O	868	869	9
O	869	870	-
O	870	875	weeks
O	875	876	)
O	876	877	,
O	878	881	and
O	882	888	follow
O	888	889	-
O	889	891	up
O	892	893	(
O	893	895	12
O	895	896	-
O	896	901	weeks
O	902	906	post
O	906	907	-
O	907	915	baseline
O	915	916	)
O	916	917	.

O	918	930	Participants
O	931	939	assigned
O	940	942	to
O	943	946	AMT
O	947	955	reported
O	956	962	higher
B-outcome	963	966	QOL
O	966	967	,
O	968	976	compared
O	977	981	with
O	982	987	those
O	988	996	assigned
O	997	999	to
O	1000	1002	WC
O	1002	1003	,
O	1004	1008	from
O	1009	1017	baseline
O	1018	1025	through
O	1026	1032	follow
O	1032	1033	-
O	1033	1035	up
O	1036	1037	t
O	1037	1038	(
O	1038	1041	258
O	1041	1042	.
O	1042	1044	40
O	1044	1045	)
O	1046	1047	=
O	1048	1049	3
O	1049	1050	.
O	1050	1052	09
O	1052	1053	,
O	1054	1055	P
O	1056	1057	<
O	1058	1059	0
O	1059	1060	.
O	1060	1062	01
O	1062	1063	,
O	1064	1066	95
O	1066	1067	%
O	1068	1070	CI
O	1071	1072	[
O	1072	1073	2
O	1073	1074	.
O	1074	1076	71
O	1076	1077	,
O	1078	1080	11
O	1080	1081	.
O	1081	1083	90
O	1083	1084	]
O	1084	1085	.

O	1086	1098	Participants
O	1099	1107	assigned
O	1108	1110	to
O	1111	1114	AMT
O	1115	1119	also
O	1120	1128	reported
O	1129	1135	higher
B-outcome	1136	1149	dispositional
I-outcome	1150	1161	mindfulness
O	1161	1162	,
O	1163	1171	compared
O	1172	1176	with
O	1177	1182	those
O	1183	1191	assigned
O	1192	1194	to
O	1195	1197	WC
O	1197	1198	,
O	1199	1203	from
O	1204	1212	baseline
O	1213	1220	through
O	1221	1227	follow
O	1227	1228	-
O	1228	1230	up
O	1231	1232	t
O	1232	1233	(
O	1233	1236	268
O	1236	1237	.
O	1237	1239	44
O	1239	1240	)
O	1241	1242	=
O	1243	1244	2
O	1244	1245	.
O	1245	1247	04
O	1247	1248	,
O	1249	1250	P
O	1251	1252	=
O	1253	1254	0
O	1254	1255	.
O	1255	1257	04
O	1257	1258	,
O	1259	1261	95
O	1261	1262	%
O	1263	1265	CI
O	1266	1267	[
O	1267	1268	0
O	1268	1269	.
O	1269	1271	01
O	1271	1272	,
O	1273	1274	0
O	1274	1275	.
O	1275	1277	57
O	1277	1278	]
O	1278	1279	.

O	1280	1283	App
O	1284	1295	utilization
O	1296	1300	data
O	1301	1304	was
O	1305	1313	obtained
O	1314	1318	from
O	1319	1321	34
O	1322	1334	participants
O	1334	1335	.

O	1336	1341	Fewer
O	1342	1354	participants
O	1355	1363	assigned
O	1364	1366	to
O	1367	1370	AMT
B-outcome	1371	1380	completed
I-outcome	1381	1384	all
I-outcome	1385	1390	study
I-outcome	1391	1402	assessments
O	1402	1403	,
O	1404	1412	compared
O	1413	1417	with
O	1418	1430	participants
O	1431	1439	assigned
O	1440	1442	to
O	1443	1445	WC
O	1445	1446	,
O	1447	1448	(
O	1448	1449	χ
O	1449	1451	21
O	1453	1454	=
O	1455	1456	7
O	1456	1457	.
O	1457	1459	07
O	1459	1460	,
O	1461	1462	P
O	1463	1464	=
O	1465	1466	0
O	1466	1467	.
O	1467	1470	008
O	1470	1471	)
O	1471	1472	.

O	1473	1481	Findings
O	1482	1489	suggest
O	1490	1502	commercially
O	1503	1512	available
O	1513	1516	AMT
O	1517	1520	may
O	1521	1528	proffer
O	1529	1533	some
O	1534	1541	benefit
O	1542	1544	to
O	1545	1550	women
O	1551	1558	seeking
O	1559	1561	to
O	1562	1569	enhance
O	1570	1575	their
O	1576	1579	QOL
O	1580	1589	following
O	1590	1596	breast
O	1597	1603	cancer
O	1604	1613	diagnosis
O	1613	1614	.
